Publicacións en colaboración con investigadores/as de Hospital Ramón y Cajal (131)

2024

  1. 18F-FDG-PET/CT response after first-line treatment as a prognostic factor for survival in peripheral T-cell lymphoma: a Spanish retrospective study

    Expert Review of Hematology, Vol. 17, Núm. 1-3, pp. 95-100

  2. A Phase I/IIa Prospective, Randomized, Open-Label Study on the Safety and Efficacy of Nebulized Liposomal Amphotericin for Invasive Pulmonary Aspergillosis

    Journal of Fungi, Vol. 10, Núm. 3

  3. COVID-19 Outcomes in Patients with Hematologic Malignancies in the Era of COVID-19 Vaccination and the Omicron Variant

    Cancers, Vol. 16, Núm. 2

  4. Comparative Review of the Current and Future Strategies to Evaluate Bone Marrow Infiltration at Diffuse Large B-Cell Lymphoma Diagnosis

    Diagnostics, Vol. 14, Núm. 6

  5. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance

    Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256

  6. Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy

    Frontiers in Oncology, Vol. 14

  7. Primary Cardiac Aggressive B-Cell Lymphoma Affecting Right Ventricle and Acute Cardiovascular Events: Multidisciplinary Approach

    JACC: Case Reports, Vol. 29, Núm. 19

  8. Real-World Experience with Isavuconazole in Allogeneic Stem Cell Transplantation in Spain

    Transplantation and Cellular Therapy, Vol. 30, Núm. 10, pp. 1033.e1-1033.e8

  9. Survival after allogeneic transplantation according to pretransplant minimal residual disease and conditioning intensity in patients with acute myeloid leukemia

    Frontiers in Oncology, Vol. 14

  10. The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

    Blood cancer journal, Vol. 14, Núm. 1, pp. 74

2023

  1. 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023

    Hematological oncology

  2. Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis

    Leukemia, Vol. 37, Núm. 7, pp. 1511-1520

  3. Assessment of the potential value of plasma Torque Teno virus DNA load monitoring to predict cytomegalovirus DNAemia in patients with hematological malignancies treated with small molecule inhibitors: A proof-of-concept study

    Journal of medical virology, Vol. 95, Núm. 7, pp. e28933

  4. COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study

    Cancers, Vol. 15, Núm. 5

  5. Enhanced thrombin generation detected with ST-Genesia analyzer in patients with newly diagnosed multiple myeloma

    Journal of Thrombosis and Thrombolysis, Vol. 55, Núm. 3, pp. 464-473

  6. Immunobiology of cytomegalovirus infection in patients with haematological malignancies undergoing treatment with small molecule inhibitors

    British Journal of Haematology, Vol. 200, Núm. 6, pp. e58-e61

  7. Invasive Pulmonary Aspergillosis in Patients with and without SARS-CoV-2 Infection

    Journal of Fungi, Vol. 9, Núm. 2

  8. LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors

    Frontiers in Immunology, Vol. 14

  9. One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients

    Blood Cancer Journal, Vol. 13, Núm. 1

  10. Patients with secondary acute myeloid leukemia undergoing allogeneic stem-cell transplant have inferior outcomes than de novo acute myeloid leukemia regardless minimal residual disease level by flow cytometry

    Hematological Oncology, Vol. 41, Núm. 4, pp. 753-761